Posted 21st October 2024
Posted 8 months ago
By Pfizer
Pfizer Shares Patient Letter re Voxelotor (Oxybryta®) Withdrawal
Pfizer Shares Patient Advice Regarding Immediate Withdrawal of Voxelotor (Oxybryta®)
Posted 10th October 2024
Posted 8 months ago
By NHP Office
Voxelotor (Oxbryta®) Withdrawal - NHP Patient Letter
Following the unforeseen Pfizer withdrawal of Voxelotor (Oxbryta®) Medication for Sickle Cell Disease on 25th September 2024, the NHP provided a letter assist affected Sickle Cell Disorder patients.
Posted 4th October 2024
Posted 8 months ago
By NHS England
NHS England on Oxbryta (Voxelotor) Withdrawal From the UK Market
NHS England sends a letter to centres regarding the 25.09.2024 withdrawal of Pfizer's Oxbryta (Voxelotor) drug for Sickle Cell Disorder.
Posted 25th September 2024
Posted 9 months ago
By NHP Office
Pfizer Withdraws OXBRYTA ® (Voxelotor) for the treatment of sickle cell disease (SCD)
On 25th September 2024, Pfizer announced its voluntarily withdrawing of all lots of OXBRYTA ® (Voxelotor) for the treatment of sickle cell disease (SCD).
Posted 9th September 2024
Posted 9 months ago
By NHS England
SOP- Casgevy (Exagamglogene Autotemcel) for Transfusion-dependent Thalassaemia
University College London have produced a Standard Operating Procedure (SOP) for the assessment and work up of exagamglogene autotemcel (Casgevy™) for transfusion-dependent beta-thalassaemia
Posted 8th August 2024
Posted 10 months ago
By NHP Office
Gene-editing therapy, Casgevy, for Transfusion Dependent Thalassaemia
On 08.08.2024 the National Institute for Health and Care Excellence (NICE) approves NHS use of Casgevy ™ [Exagamglogene Autotemcel (‘Exa-Cel’)] for treatment of Transfusion-dependent beta Thalassaemia
Posted 26th January 2022
Posted 3 years ago
By NHP Office
New Therapies Session- ASCAT 2022
View 3 insightful presentations with Q&A from the New Therapies Session at the virtual ASCAT 2022.
